UroGen Pharma Ltd.
URGNNext catalyst
UGN-103
recurrent low-grade intermediate-risk non–muscle invasive bladder cancer
Get an email about URGN's next catalysts
Track UroGen Pharma (URGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 3 readout, earnings).See the timeline
3 upcoming, 1 past
UGN-104 Phase 3 Est. Readout
Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carcinoma
SourceURGN Earnings Report
EPS Est: $0.05 | FQ end Sep/2026 | Call: bmo
FDA PDUFA Date UGN-103
For recurrent low-grade intermediate-risk non–muscle invasive bladder cancer. nda filing. AI-extracted from news: <![CDATA[FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC]]>
SourceUpcoming FDA decisions
How URGN's past catalysts played out
Market Overview
Stock performance and key metrics
UGN-101 instillations
Carcinoma, Transitional Cell
UGN-102
Bladder Cancer
UGN-104
Upper Urinary Tract Urothelial Carcinoma
UGN-103
Bladder Cancer
MMC in
Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UGN-101 instillations | Phase 3 | Carcinoma, Transitional Cell | - | - |
UGN-102 | Phase 3 | Bladder Cancer | - | - |
UGN-104 | Phase 3 | Upper Urinary Tract Urothelial Carcinoma | - | - |
UGN-103 | Phase 3 | Bladder Cancer | - | - |
MMC in | Phase 2 | Bladder Cancer | - | - |
Frequently asked questions
What is in UroGen Pharma Ltd.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in UroGen Pharma Ltd.'s (URGN) pipeline across Phase 3, Phase 2. Its lead program is UGN-103 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is UroGen Pharma Ltd.'s next FDA catalyst?→
UroGen Pharma Ltd.'s (URGN) next tracked catalyst is a PDUFA date expected Jun 14, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track URGN biotech catalysts?→
Add URGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UroGen Pharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
